肝硬度值 vs. 生化应答对原发性胆汁性胆管炎的预后价值
这项国际多中心研究纳入1793例原发性胆汁性胆管炎(PBC)患者,中位随访22个月,比较肝硬度测量(LSM)与生化应答(Paris-II标准)不一致时的预后价值。结果发现55%患者LSM与生化应答不一致,当前LSM>10 kPa强烈预测首次肝失代偿(HR 14.5,95%CI 6.9-30.6,p<0.001),且不受既往生化应答或LSM轨迹影响。
要点
- PBC患者中LSM与生化应答不一致常见,可达55%。
- 当前LSM>10 kPa是首次肝失代偿的最强预测因子(HR 14.5)。
- 已知当前LSM后,既往LSM轨迹和生化变化不改善预测。
核心结论
- LSM与生化应答不一致在PBC患者中频繁出现。
- 当前或最近一次LSM是PBC患者首次肝脏相关事件的最强预测因子,不受既往生化应答或LSM轨迹影响。
研究设计与样本
- 国际多中心研究,纳入至少两次可靠LSM(间隔至少6个月)的PBC患者,排除既往肝失代偿、肝移植或肝细胞癌者。
- 共分析1793例PBC患者,中位随访22个月(IQR 12-39)。
主要发现
- 随访期间3.3%患者发生首次肝失代偿。
- 高达55%的PBC患者存在LSM与生化应答不一致。
- 在LSM应答患者中,达到Paris-II标准与较低肝失代偿风险相关(HR 0.25,95%CI 0.06-0.97,p<0.044)。
- 在生化应答患者中,LSM应答不影响肝失代偿风险(HR 0.64,95%CI 0.21-1.96,p=0.429)。
- 当前LSM>10 kPa强烈预测肝失代偿(HR 14.5,95%CI 6.9-30.6,p<0.001),不受生化应答和既往LSM轨迹影响。
关键数值与推荐
- 生化应答基于Paris-II标准。
- LSM应答定义为LSM稳定或任何程度下降。
- 当前LSM>10 kPa的肝失代偿风险HR为14.5(95%CI 6.9-30.6,p<0.001)。
临床怎么用
- 对于多次LSM读数的PBC患者,使用最新LSM值进行风险分层可简化临床决策。
- 当前LSM>10 kPa提示肝失代偿高风险,应加强监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Both liver stiffness measurement (LSM) and biochemical response have prognostic significance in patients with primary biliary cholangitis (PBC). However, the frequency and clinical relevance of discordant biochemical and LSM changes remain unclear. We aim to determine the performance of the most recent or current LSM (LSMc) in predicting first hepatic decompensation (HD) in the setting of discordant biochemical and LSM responses. METHODS: In this international, multicenter study, we included patients with at least two reliable LSM performed at least 6 months apart. Patients with prior HD, liver transplantation or hepatocellular carcinoma were excluded. Biochemical response was based on the Paris-II criteria. LSM response was defined as stable or any reduction in LSM. The primary outcome was the occurrence of the first HD. Secondary outcomes were liver transplantation and liver-related death. The influence of LSM on HD was estimated using Cox regression analysis. RESULTS: A total of 1,793 patients with PBC were analyzed. Over a median follow-up of 22 (IQR 12-39) months, 3.3% developed HD. Up to 55% of patients with PBC exhibited discordance between LSM and biochemical response. Among patients with LSM response, achieving Paris-II criteria was associated with a lower risk of HD (hazard ratio [HR] 0.25, 95% CI 0.06-0.97, p <0.044). Among patients with biochemical response, LSM response did not influence the risk of developing HD (HR 0.64, 95% CI 0.21-1.96, p = 0.429). The LSMc >10 kPa strongly predicted HD (HR 14.5, 95% CI 6.9-30.6, p <0.001), irrespective of biochemical response and prior LSM trajectories. CONCLUSIONS: Discordance between LSM and biochemical response is frequent. Most recent or current LSM is the strongest predictor of first liver-related events in patients with PBC, irrespective of prior biochemical response or LSM trajectory. IMPACT AND IMPLICATIONS: Both liver stiffness measurement (LSM) and biochemical response have prognostic significance in patients with primary biliary cholangitis. However, the clinical relevance and how discordant biochemical and LSM changes should be best interpreted remain unclear. In this large international multicenter study, we demonstrated that once the current LSM is known, prior LSM trajectories and biochemical changes did not improve the prediction of liver-related events in patients with primary biliary cholangitis. Our finding addresses a common clinical dilemma in risk-stratifying PBC patients with discordant biochemical and LSM responses. Importantly, the use of the latest LSM value for risk prediction significantly simplifies the use of LSM in clinical decision-making for PBC patients with multiple LSM readings.
引用
- Wong YJ, Lam L, Soret PA, et al. Prognostic value of liver stiffness measurement vs. biochemical response in primary biliary cholangitis. J Hepatol. 2025. PMID: 41047080. doi:10.1016/j.jhep.2025.09.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。